Enrollments up in OCT. Should translate in higher sales for the next 2 quarters.
Third q was mostly booked when he made that statement. Your speculation does not change that fact.. I would expect Zitiga and Xantdi and Provenge sales to all continue to rise simultaneously..
JJ said sales were increasing into this upcoming quarter.
Except the opposite is true cash burn decreasing and sales increasing per the last cc.,
Tumor shrinkage irrelevant if survival not impacted.
We all know what happens to greedy little pigs.
Todays action was shorting not selling real shares.